• BigBear Pharma: Statement on the Investigation into Quality Defects of Sealing Stickers on Certain Drug Products

  Dear Customers, Partners, and Relevant Parties,During a recent product quality inspection bigbear pharma discovered that the sealing stickers used on ···【Read More】

  Update: 10 Sep,2026Source: Haiou HealthViews: 91

• Remibrutinib Significantly Reduces Relapse Rate and Shows Favorable Safety in Phase III Trial for New Indication in Relapsing Multiple Sclerosis (RMS)

  On September 1, 2026, local time, Novartis announced positive topline results from the Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib in rel···【Read More】

  Update: 07 Sep,2026Source: Haiou HealthViews: 107

• Zanvastro (zilganersen) Approved in the U.S. for the Treatment of Rare Alexander Disease

  On September 3, 2026, the U.S. Food and Drug Administration (FDA) approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in···【Read More】

  Update: 04 Sep,2026Source: Haiou HealthViews: 115

• Selpercatinib (SEPADX) manufactured by BigBear Pharma has received approval in Laos

  Vientiane, Laos - November 20, 2023 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer ···【Read More】

  Update: 18 Aug,2026Source: Haiou HealthViews: 141

• BigBear Pharma: Product Update Announcement for Baricitinib (BARUDX)

  Dear Customers, Partners, and Relevant Parties:Our company BigBear PharmaBaricitinib Tablets adopts pink coating powder for film coating. To further o···【Read More】

  Update: 13 Aug,2026Source: Haiou HealthViews: 150

• BigBear Pharma: Product Update Notice for Osimertinib(OYSIENDX)

  Dear Customers, Partners and Relevant Entities,The film‑coating of Osimertinib Tablets manufactured by BigBear Pharma Co., Limited uses light‑brown co···【Read More】

  Update: 11 Aug,2026Source: Haiou HealthViews: 146

• bigbear pharma: Product Update Announcement for Ivosidenib (AIVODX)

  Dear Customers, Partners, and Relevant Parties:Our companyBigBear Pharmauses blue coating powder for film coating of Ivosidenib tablets. Due to the re···【Read More】

  Update: 07 Aug,2026Source: Haiou HealthViews: 153

• bigbear pharma: Product Update Announcement for Apalutamide (APADX)

  Dear Customers, Partners and Relevant Parties:Our companyBigBear Pharma uses light brown coating powder for film coating of Apalutamide Tablets. To fu···【Read More】

  Update: 05 Aug,2026Source: Haiou HealthViews: 149

• FDA has approved Lytenava (bevacizumab-vikg) for neovascular age-related macular degeneration (nAMD)

  On July 24, 2026 local time, Outlook Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Lytenava (bevacizumab-···【Read More】

  Update: 03 Aug,2026Source: Haiou HealthViews: 130

• bigbear pharma:Product Update Announcement for Avatrombopag (AVATODX)

  Dear Customers, Partners and Relevant Entities:Our company, Bear Pharmaceutical Co., Ltd., uses light yellow coating powder for film coating of Avatro···【Read More】

  Update: 31 Jul,2026Source: Haiou HealthViews: 145

• bigbear pharma: Adagrasib (ADADX) Product Update Announcement

  Dear Customers, Partners and Relevant Parties:Our company, Daewoong Pharmaceutical Co., Ltd., uses white coating powder for film coating of Adagrasib.···【Read More】

  Update: 28 Jul,2026Source: Haiou HealthViews: 171

• Lao BigBear Pharmaceuticals obtains GMP certification for its traditional medicine processing plant, bringing its quality system to a new international stage

  BigBear Pharmaceuticals (Lao) has announced that its traditional medicine processing plant has successfully passed GMP (Good Manufacturing Practice) c···【Read More】

  Update: 13 Jul,2026Source: Haiou HealthViews: 210

• FDA approves Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease!

  Local time June 26, 2026, Viridian Therapeutics, Inc., a biotechnology company focused on discovering, developing, and commercializing potential best-···【Read More】

  Update: 01 Jul,2026Source: Haiou HealthViews: 213

• Sanofi’s Tzield Approved in the US as the First Disease-Modifying Therapy for Patients Recently Diagnosed with Stage 3 Type 1 Diabetes

  Paris, June 13, 2026. The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in e···【Read More】

  Update: 16 Jun,2026Source: Haiou HealthViews: 244

• FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease

  On 15 May 2026, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) and atezolizumab and hyaluronidase-tqjs (···【Read More】

  Update: 12 Jun,2026Source: Haiou HealthViews: 290